RECIST 1.1—Update and clarification: From the RECIST committee


      • Clarification on how to select target lesions and what to do with measurable lesions which are not selected for target disease response assessment.
      • Clarification on the definition of stable disease.
      • Clarification on the role of Fluorodeoxy-glucose (18F) (FDG)-positron emission tomography (PET)/PET-computed tomography in the context of RECIST 1.1.


      The Response Evaluation Criteria in Solid Tumours (RECIST) were developed and published in 2000, based on the original World Health Organisation guidelines first published in 1981. In 2009, revisions were made (RECIST 1.1) incorporating major changes, including a reduction in the number of lesions to be assessed, a new measurement method to classify lymph nodes as pathologic or normal, the clarification of the requirement to confirm a complete response or partial response and new methodologies for more appropriate measurement of disease progression. The purpose of this paper was to summarise the questions posed and the clarifications provided as an update to the 2009 publication.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Miller A.B.
        • Hoogstraten B.
        • Staquet M.
        • Winkler A.
        Reporting results of cancer treatment.
        Cancer. 1981; 47: 207-214
        • Therasse P.
        • Arbuck S.G.
        • Eisenhauer E.A.
        • Wanders J.
        • Kaplan R.S.
        • Rubinstein L.
        • Verweij J.
        • Van Glabbeke M.
        • van Oosterom A.T.
        • Christian M.C.
        • Gwyther S.G.
        New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
        J Natl Cancer Inst. 2000; 92: 205-216
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • Schwartz L.H.
        • Sargent D.
        • Ford R.
        • Dancey J.
        • Arbuck S.
        • Gwyther S.
        • Mooney M.
        • Rubinstein L.
        • Shankar L.
        • Dodd L.
        • Kaplan R.
        • Lacombe D.
        • Verweij J.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Janku F.
        • Berry D.A.
        • Gong J.
        • Parsons H.A.
        • Stewart D.J.
        • Kurzrock R.
        Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non–small cell lung cancer published between 2000 and 2009.
        Clin Cancer Res. 2012; 18: 6356-6363

        • Zhao B.
        • Tan Y.
        • Bell D.J.
        • Marley S.E.
        • Guo P.
        • Mann H.
        • Scott M.L.
        • Schwartz L.H.
        • Ghiorghiu D.C.
        Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals.
        Eur J Radiol. 2013; 82: 959-968
        • Sullivan D.C.
        • Schwartz L.H.
        • Zhao B.
        The imaging viewpoint: how imaging affects determination of progression-free survival.
        Clin Cancer Res. 2013; 19: 2621-2628